1. Department of General Surgery, Huashan Hospital, Cancer Metastasis Institute, Fudan University, Shanghai 200040, China 2. Kanion Research Institute, Lianyungang 222002, China 3. Institutes of Biomedical Sciences, Fudan University, Shanghai 200040, China
Cabozantinib, mainly targeting cMet and vascular endothelial growth factor receptor 2, is the second-line treatment for patients with advanced hepatocellular carcinoma (HCC). However, the lower response rate and resistance limit its enduring clinical benefit. In this study, we found that cMet-low HCC cells showed primary resistance to cMet inhibitors, and the combination of cabozantinib and mammalian target of rapamycin (mTOR) inhibitor, rapamycin, exhibited a synergistic inhibitory effect on the in vitro cell proliferation and in vivo tumor growth of these cells. Mechanically, the combination of rapamycin with cabozantinib resulted in the remarkable inhibition of AKT, extracellular signal-regulated protein kinases, mTOR, and common downstream signal molecules of receptor tyrosine kinases; decreased cyclin D1 expression; and induced cell cycle arrest. Meanwhile, rapamycin enhanced the inhibitory effects of cabozantinib on the migration and tubule formation of human umbilical vascular endothelial cells and human growth factor-induced invasion of cMet inhibitor-resistant HCC cells under hypoxia condition. These effects were further validated in xenograft models. In conclusion, our findings uncover a potential combination therapy of cabozantinib and rapamycin to combat cabozantinib-resistant HCC.
F Bray, J Ferlay, I Soerjomataram, RL Siegel, LA Torre, A Jemal. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68(6): 394–424 https://doi.org/10.3322/caac.21492
pmid: 30207593
JD Yang, P Hainaut, GJ Gores, A Amadou, A Plymoth, LR Roberts. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol 2019; 16(10): 589–604 https://doi.org/10.1038/s41575-019-0186-y
pmid: 31439937
FM Yakes, J Chen, J Tan, K Yamaguchi, Y Shi, P Yu, F Qian, F Chu, F Bentzien, B Cancilla, J Orf, A You, AD Laird, S Engst, L Lee, J Lesch, YC Chou, AH Joly. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 2011; 10(12): 2298–2308 https://doi.org/10.1158/1535-7163.MCT-11-0264
pmid: 21926191
6
GK Abou-Alfa, T Meyer, AL Cheng, AB El-Khoueiry, L Rimassa, BY Ryoo, I Cicin, P Merle, Y Chen, JW Park, JF Blanc, L Bolondi, HJ Klümpen, SL Chan, V Zagonel, T Pressiani, MH Ryu, AP Venook, C Hessel, AE Borgman-Hagey, G Schwab, RK Kelley. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med 2018; 379(1): 54–63 https://doi.org/10.1056/NEJMoa1717002
pmid: 29972759
7
JM Llovet, R Montal, D Sia, RS Finn. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol 2018; 15(10): 599–616 https://doi.org/10.1038/s41571-018-0073-4
pmid: 30061739
8
S Faivre, G Kroemer, E Raymond. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006; 5(8): 671–688 https://doi.org/10.1038/nrd2062
pmid: 16883305
9
F Chiarini, C Evangelisti, JA McCubrey, AM Martelli. Current treatment strategies for inhibiting mTOR in cancer. Trends Pharmacol Sci 2015; 36(2): 124–135 https://doi.org/10.1016/j.tips.2014.11.004
pmid: 25497227
10
A Carracedo, L Ma, J Teruya-Feldstein, F Rojo, L Salmena, A Alimonti, A Egia, AT Sasaki, G Thomas, SC Kozma, A Papa, C Nardella, LC Cantley, J Baselga, PP Pandolfi. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008; 118(9): 3065–3074 https://doi.org/10.1172/JCI34739
pmid: 18725988
Y Zhang, X Gao, Y Zhu, D Kadel, H Sun, J Chen, Q Luo, H Sun, L Yang, J Yang, Y Sheng, Y Zheng, K Zhu, Q Dong, L Qin. The dual blockade of MET and VEGFR2 signaling demonstrates pronounced inhibition on tumor growth and metastasis of hepatocellular carcinoma. J Exp Clin Cancer Res 2018; 37(1): 93 https://doi.org/10.1186/s13046-018-0750-2
pmid: 29712569
E Gherardi, W Birchmeier, C Birchmeier, G Vande Woude. Targeting MET in cancer: rationale and progress. Nat Rev Cancer 2012; 12(2): 89–103 https://doi.org/10.1038/nrc3205
pmid: 22270953
15
A D’Errico, M Fiorentino, A Ponzetto, Y Daikuhara, H Tsubouchi, C Brechot, JY Scoazec, WF Grigioni. Liver hepatocyte growth factor does not always correlate with hepatocellular proliferation in human liver lesions: its specific receptor c-met does. Hepatology 1996; 24(1): 60–64 https://doi.org/10.1053/jhep.1996.v24.pm0008707284
pmid: 8707284
16
P Kaposi-Novak, JS Lee, L Gòmez-Quiroz, C Coulouarn, VM Factor, SS Thorgeirsson. Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest 2006; 116(6): 1582–1595 https://doi.org/10.1172/JCI27236
pmid: 16710476
17
L Rimassa, E Assenat, M Peck-Radosavljevic, V Zagonel, M Pracht, ER Caremoli, P Mathurin, WP Harris, L Bolondi, M Reig, N Damjanov, B Daniele, C Porta, V Mazzaferro, G Abbadessa, BE Schwartz, M Lamar, TR Goldberg, A Santoro, J Bruix. Second-line tivantinib (ARQ 197) vs placebo in patients (Pts) with MET-high hepatocellular carcinoma (HCC): Results of the METIV-HCC phase III trial. J Clin Oncol 2017; 35(15 suppl): 4000 https://doi.org/10.1200/JCO.2017.35.15_suppl.4000
X Li, MT Lewis, J Huang, C Gutierrez, CK Osborne, MF Wu, SG Hilsenbeck, A Pavlick, X Zhang, GC Chamness, H Wong, J Rosen, JC Chang. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008; 100(9): 672–679 https://doi.org/10.1093/jnci/djn123
pmid: 18445819
21
J Bruix, LG da Fonseca, M Reig. Insights into the success and failure of systemic therapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2019; 16(10): 617–630 https://doi.org/10.1038/s41575-019-0179-x
pmid: 31371809
22
Z Ezzoukhry, C Louandre, E Trécherel, C Godin, B Chauffert, S Dupont, M Diouf, JC Barbare, JC Mazière, A Galmiche. EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib. Int J Cancer 2012; 131(12): 2961–2969 https://doi.org/10.1002/ijc.27604
pmid: 22514082
23
DY Chiang, A Villanueva, Y Hoshida, J Peix, P Newell, B Minguez, AC LeBlanc, DJ Donovan, SN Thung, M Solé, V Tovar, C Alsinet, AH Ramos, J Barretina, S Roayaie, M Schwartz, S Waxman, J Bruix, V Mazzaferro, AH Ligon, V Najfeld, SL Friedman, WR Sellers, M Meyerson, JM Llovet. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res 2008; 68(16): 6779–6788 https://doi.org/10.1158/0008-5472.CAN-08-0742
pmid: 18701503
24
Y Hoshida, SM Nijman, M Kobayashi, JA Chan, JP Brunet, DY Chiang, A Villanueva, P Newell, K Ikeda, M Hashimoto, G Watanabe, S Gabriel, SL Friedman, H Kumada, JM Llovet, TR Golub. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res 2009; 69(18): 7385–7392 https://doi.org/10.1158/0008-5472.CAN-09-1089
pmid: 19723656
25
S Boyault, DS Rickman, A de Reyniès, C Balabaud, S Rebouissou, E Jeannot, A Hérault, J Saric, J Belghiti, D Franco, P Bioulac-Sage, P Laurent-Puig, J Zucman-Rossi. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 2007; 45(1): 42–52 https://doi.org/10.1002/hep.21467
pmid: 17187432
A Villanueva, DY Chiang, P Newell, J Peix, S Thung, C Alsinet, V Tovar, S Roayaie, B Minguez, M Sole, C Battiston, S Van Laarhoven, MI Fiel, A Di Feo, Y Hoshida, S Yea, S Toffanin, A Ramos, JA Martignetti, V Mazzaferro, J Bruix, S Waxman, M Schwartz, M Meyerson, SL Friedman, JM Llovet. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 2008; 135(6): 1972–1983.e1–11 https://doi.org/10.1053/j.gastro.2008.08.008
pmid: 18929564
29
Y Imura, H Yasui, H Outani, T Wakamatsu, K Hamada, T Nakai, S Yamada, A Myoui, N Araki, T Ueda, K Itoh, H Yoshikawa, N Naka. Combined targeting of mTOR and c-MET signaling pathways for effective management of epithelioid sarcoma. Mol Cancer 2014; 13(1): 185 https://doi.org/10.1186/1476-4598-13-185
pmid: 25098767
GL Semenza. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci 2012; 33(4): 207–214 https://doi.org/10.1016/j.tips.2012.01.005
pmid: 22398146
33
H You, W Ding, H Dang, Y Jiang, CB Rountree. c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma. Hepatology 2011; 54(3): 879–889 https://doi.org/10.1002/hep.24450
pmid: 21618573
34
V Finisguerra, G Di Conza, M Di Matteo, J Serneels, S Costa, AA Thompson, E Wauters, S Walmsley, H Prenen, Z Granot, A Casazza, M Mazzone. MET is required for the recruitment of anti-tumoural neutrophils. Nature 2015; 522(7556): 349–353 https://doi.org/10.1038/nature14407
pmid: 25985180
35
C Zhu, Y Wei, X Wei. AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications. Mol Cancer 2019; 18(1): 153 https://doi.org/10.1186/s12943-019-1090-3
pmid: 31684958
36
AY Li, MG McCusker, A Russo, KA Scilla, A Gittens, K Arensmeyer, R Mehra, V Adamo, C Rolfo. RET fusions in solid tumors. Cancer Treat Rev 2019; 81: 101911 https://doi.org/10.1016/j.ctrv.2019.101911
pmid: 31715421